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Abstract 
Extracellular vesicles (EVs) are membrane particles involved in the exchange 
of a broad range of bioactive molecules between cells and the 
microenvironment. While it has been shown that cells can traffic metabolic 
enzymes via EVs much remains to be elucidated with regard to their intrinsic 
metabolic activity. Accordingly, herein we assessed the ability of neural 
stem/progenitor cell (NSC)-derived EVs to consume and produce metabolites. 
Both our metabolomics and functional analyses revealed that EVs harbour L-
asparaginase activity catalysed by the enzyme Asparaginase-like protein 1 
(Asrgl1). Critically, we show that Asrgl1 activity is selective for asparagine and 
is devoid of glutaminase activity. We found that mouse and human NSC-
derived EVs traffic ASRGL1. Our results demonstrate for the first time that 
NSC EVs function as independent, extracellular metabolic units able to modify 
the concentrations of critical nutrients, with the potential to affect the 
physiology of their microenvironment.  
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Introduction 
Extracellular vesicles (EVs) are a heterogeneous group of membrane 
particles secreted by the majority of cell types across all kingdoms of life; they 
have different mechanisms of biogenesis, structural composition, and 
functions1. Of these, shedding vesicles, exosomes and apoptotic bodies have 
been the most studied subtypes of EVs to date2. Several studies aimed at 
characterizing the content of EVs and went on to demonstrate that a broad 
range of bioactive molecules, including proteins and different types of nucleic 
acids, are associated with EVs3,4. Of note, the content of EVs can vary 
according to the cell type of origin, and/or in response to stimuli from the 
microenvironment5. We previously demonstrated that neural stem cells 
(NSCs) secrete EVs containing mRNAs and proteins, whose sorting is 
regulated by inflammatory cytokines. Our study identified a novel mechanism 
of intercellular communication regulated by the IFN-/Ifngr1 complex on EVs 
and elucidated its molecular signature and functional relevance to target 
cells6.  
A growing body of evidence supports a key a role for EVs in regulating 
metabolic homeostasis or associated cellular processes. For instance, 
glucose deprivation was shown to promote trafficking of glucose transporters 
and glycolytic enzymes towards EVs in cardiomyocytes7. Prostate-derived, 
exosome-like prostasomes harbor enzymes involved in adenosine 
triphosphate (ATP) metabolic turnover that include adenylate kinase, ATPase, 
5'-nucleotidase, and hexose transporters8. One quarter of the proteins 
enriched in prostate cancer-derived EVs large oncosomes (vs. prostate 
cancer cells) includes enzymes involved in glucose, glutamine and amino acid 
metabolism9. Furthermore, primary B-cell precursor acute lymphoblastic 
leukemia cells release a variety of EVs into extracellular fluids (in vitro) and 
circulation (in vivo) that are internalized by stromal cells, which subsequently 
undergo a metabolic switch toward a glycolytic phenotype10. Finally, cancer-
associated fibroblasts -derived EVs induce central carbon metabolism in 
target cells and promote tumor growth under nutrient deprivation or nutrient 
stressed conditions11. It has been recently hypothesized that EVs are involved 
in the intercellular trafficking of small molecules11. However, whether EVs can 
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act as independent, metabolically active units, capable of perturbing the 
extracellular milieu is still unknown. In this work, we sought to investigate the 
enzymatic activities associated with NSC-derived EVs. We found that NSC 
EVs are metabolically active and, in particular, that they exhibit L-
asparaginase activity. We identified asparaginase-like protein 1 (Asrgl1) as 
the key metabolic enzyme responsible for the L-asparaginase activity of EVs. 
Finally, we observed that EV-associated Asrgl1 is specific for asparagine 
(Asn) and is devoid of glutaminase activity. Our study shows for the first time 
that EVs can behave as autonomous metabolic reactors and are capable of 
delivering specific and functional L-asparaginase activity to the 
microenvironment via Asrgl1. 
 
 
Results 
NSCs secrete EVs containing exosomes 
We started our investigation by generating EVs from NSCs. Stably 
expandable NSCs were derived from the subventricular zone of adult mice, 
and EVs were purified from NSC supernatants by differential centrifugation 
(Supplementary Results, Supplementary Fig. 1a), as previously 
described6. To characterize the population of vesicles secreted by NSCs, we 
applied a combination of nanoparticle tracking analysis (NTA), tunable 
resistive pulse sensing (TRPS) technology and Western blot (WB) analysis. 
NTA identified a major peak (169 ± 3 nm) in the size range of exosomes, and 
a minor peak (300–500 nm), which is consistent with the dimension of larger 
shedding vesicles (Fig. 1a). TRPS with a 150 nm nanopore confirmed the 
presence of small vesicles, with a major peak corresponding to the size 
described for exosomes (102 ± 9 nm) (Fig. 1b)12. WB analyses further 
confirmed that protein extracts purified from EVs are specifically enriched in 
markers associated with exosomes (vs. parental NSC protein extracts), which 
include Pdcd6ip, Tsg101 and the tetraspanins CD63 and CD9. On the other 
hand, markers for other cellular compartments, such as Golga2 (Golgi), 
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Calnexin (Endoplasmic reticulum) and Tomm20 (Mitochondria) did not show a 
similar distribution (Fig. 1c). 
 
NSC-derived EVs exhibit L-asparaginase activity 
To assess the metabolic activity of NSC EVs, we incubated EVs in 
commercial NSC medium and analysed the consumption/release of 
metabolites from/in the medium via liquid chromatography coupled to mass 
spectrometry (LC-MS) (Supplementary Fig. 1b). We observed that 
incubation with EVs induced profound changes in the levels of several 
metabolites within the medium (Supplementary Tab. 1). Importantly, heat 
inactivation suppressed this metabolic activity of EVs (Supplementary Fig. 
2a), suggesting that consumption and release of metabolites is largely due to 
the intrinsic enzymatic activity of EVs and not to leakage of metabolites. We 
found that Asn was the most consumed metabolite out of two independent 
EVs preparations, whilst aspartate (Asp) and glutamate (Glu) were amongst 
the most abundantly released metabolites (Fig. 2a). Given the significant 
depletion of Asn coupled with the production of Asp, we hypothesised that 
EVs harbour L-asparaginase activity. To validate this hypothesis, we 
incubated EVs in commercial NSC medium supplemented with 15N2-Asn. If 
EVs carried L-asparaginase activity, 15N-Aspartate should be found in the EV 
spent medium (Supplementary Fig. 2b). Consistent with this hypothesis, we 
observed marked consumption of 15N2-Asn coupled with production of 
15N-
Asp in media containing EVs (Fig. 2b). Of note, EVs exhibited enriched L-
asparaginase activity compared to NSC conditioned media (CM) and EV-
deprived NSC supernatants (SN). Furthermore, L-asparaginase activity was 
dampened in heat-inactivated vesicles (Fig. 2b), confirming that this activity 
depends on intact enzymatic function. Importantly, we found that also NSCs 
exhibited L-asparaginase activity, as indicated by the uptake of asparagine 
and intracellular conversion of 15N2-asparagine to 
15N-aspartate 
(Supplementary Fig. 2c). Finally, a calibration curve using clinical-grade L-
asparaginase produced by Erwinia chrysanthemi (Erwinase) allowed us to 
quantify the intrinsic L-asparaginase activity of NSC EVs, giving a value of 
2x10–6 U/g of EV protein (Fig. 2c). 
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Mouse and human NSCs traffic Asrgl1 into EVs  
We then investigated the identity of the possible enzymes that might confer 
such asparaginase activity to NSC-derived EVs. The mouse genome contains 
two L-asparaginases: a 60 kDa lysophospholipase/L-asparaginase (Aspg) 
and an isoaspartyl peptidase/L-asparaginase (Asparaginase-like protein 1; 
Asrgl1) (source http://www.uniprot.org). To assess the expression of Aspg 
and Asrgl1 in NSCs we took advantage of a comprehensive long RNA-seq 
analysis that we recently published6, and found that NSCs express Asrgl1 but 
not Aspg (Supplementary Fig. 3a).  
Independent qPCR and WB analyses confirmed the RNA-seq data and 
showed that EV protein extracts contained Asrgl1 at levels comparable to 
parental NSCs (Fig. 3a-b). We then assessed the distribution of the enzyme 
in EVs subjected to sucrose gradient fractionation. We found that Asrgl1 
peaks at 1.13 g/ml, overlapping with the exosome fraction, both in terms of 
markers (i.e. Pdcd6ip, Tsg101, CD63 and CD9) and density (1.13–1.20 g/ml), 
as described13 (Fig. 3c). We also excluded that Asrgl1 was present in 
fractions enriched into protein aggregates (density ≥1.21 g/ml)14 (Fig. 3c), 
thus unambiguously demonstrating that Asrgl1 is genuinely associated with 
EVs (e.g. shedding vesicles and exosomes). 
Next, we extended our analyses to clinical grade human foetal NSCs 
(hNSCs)15, as well as to EVs collected from hNSC supernatants. Similar to 
mouse NSCs, hNSCs expressed ASRGL1, but not ASPG, and hNSCs-
derived EVs contained ASGRL1 (Supplementary Fig. 3b-c).  
Thus, EVs from both mouse and human NSCs are cargoed with Asrgl1. 
 
Asrgl1 catalyses the L-asparaginase activity of EVs 
Asrgl1 has been described to be associated to small exosome-like vesicles 
called prostasomes16, but its metabolic function in EVs remains to be defined. 
In vitro experiments indicate that, differently from Aspg, Asgrl1 activity is 
devoid of enzymatic activity towards glutamine (Gln)17. Therefore, we wanted 
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to investigate substrate specificity of EV-associated Asrgl1. We first tested 
whether EVs exhibit any glutaminase (Gls) activity. To this aim, we incubated 
EVs with 13C-Gln and measured the production of 13C-Glu, the product of Gls 
activity (See Supplementary Fig. 4a for a schematic of the experiment). We 
could detect Gln consumption by EVs and this was associated with the 
production of 13C-Glu (Supplementary Fig. 4b). Heat inactivation abolished 
Gln consumption and Glu production by EVs, indicating that this activity 
requires the presence of intact enzymes. In line with this finding, we detected 
protein expression of Gls in EVs (Fig. 4a-b). 
To confirm that Asrgl1 is the L-asparaginase responsible for the EV-
mediated hydrolysis of Asn to Asp, and further exclude any possible Asrgl1-
related Gls activity, we performed loss- (LoF) and gain-of-function (GoF) 
experiments by transducing NSCs with either a short hairpin RNA targeting 
Asrgl1 (shAsrgl1) or with the Asrgl1 coding sequence. NSC transduction with 
LoF and GoF lentiviral vectors did not affect NSC growth and viability upon 
serial passaging in vitro (Supplementary Fig. 5). LoF and GoF NSCs and 
EVs showed effective reductions and increases in the levels of Asrgl1 
expression, respectively, as compared to controls. Of note, these changes in 
the expression of Asrgl1 had no effects on the level of other endogenous 
enzymes, such as Gls, both in NSC and EVs (Fig. 4a-b).  
We then assessed the relative metabolic activity of EV-trafficked Asrgl1 by 
incubating control, LoF and GoF EVs in cell culture media containing equal 
amounts of Asn and Gln. Consumption of 15N2-Asn and production of 
15N-Asp 
were significantly reduced in media incubated with shAsrgl1 EVs (vs. shCtrl 
EVs) (Fig. 4c). Conversely, we observed a significant increase in the 
consumption of 15N2-Asn and production of 
15N-Asp within media incubated 
with Asrgl1 GoF EVs (vs. Ctrl EVs) (Fig. 4d). Importantly, incubation of media 
with both shAsrgl1 EVs and Asrgl1 GoF EVs did not alter the consumption of 
13C5- Gln or the production of 
13C5-Glu (Fig. 4c-d), confirming that Asrgl1 
activity is specific for Asn and is devoid of Gls activity. Finally, we compared 
the L-asparaginase activity of EVs to that of parental cells and of human 
recombinant ASRGL1. We used the latter as reference to estimate by western 
blotting the relative abundance of Asgrl1 in NSCs and EVs, both Ctrl and 
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GoF. Interestingly, we found that NSCs and EVs both exhibit much higher 
Asgrl1-dependent L-asparaginase activity, compared to the recombinant 
protein (Supplementary Fig. 6).  
 
 
Discussion 
EVs are influential players in intercellular communication where they 
participate via exchanging lipids, proteins, and nucleic acids. Depending on 
their origin and cargo molecules, EVs can modulate immune-regulatory 
processes, set up tumor escape mechanisms and/or mediate regenerative or 
degenerative processes18. The extent to which EVs interact with and 
modulate intracellular signaling pathways within target cells is not yet fully 
understood19. 
We have recently shown that NSC EVs carrying receptor proteins within 
their cargo, including inflammatory cytokine receptors, activate downstream 
canonical signaling pathways in target cells, a mechanism that grafted stem 
cells might use to communicate with the host immune system6. More complex 
mechanisms, however, are emerging. These include direct gene and/or 
protein delivery, or transfer of non-coding small RNAs (e.g. microRNAs) 
functioning in RNA silencing and post-transcriptional regulation of gene 
expression20. The level of complexity in the understanding of signaling 
properties of EVs increases along with the knowledge that (i) individual cells 
release different subtypes of EVs simultaneously and that intercellular 
communication often involves more than two cells; (ii) trafficking of 
messengers into EVs varies in response to perturbations and stresses, 
including cytokines and growth factors, relative levels of extra- or intra-cellular 
amino acids21, hypoxia/normoxia, shear stress and circadian rhythms22,23; and 
(iii) available techniques to collect, process and analyze EVs and EV-induced 
cellular responses remain suboptimal24. 
Emerging evidence suggests that EVs from different cell types can act as 
metabolic regulators7-10,25, yet the characterization of EVs intrinsic metabolic 
activity is still debated. By applying state-of-the-art untargeted and targeted 
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metabolomic analyses, we demonstrated that NSC EVs exhibit enzymatic 
activities that affect the consumption/release of metabolites in the extracellular 
compartment. This important observation suggests that EVs are metabolically 
active and that multiple enzymes are associated with EVs. Unexpectedly, we 
found that Asn is the most significantly consumed metabolite suggesting a 
predominant L-asparaginase activity associated with EVs. Of note, this L-
asparaginase activity was observed in NSCs, strongly suggesting that EVs do 
not acquire this metabolic function de novo but, rather, that this activity is 
transferred from the donor cells. This hypothesis has important implications: 
whilst L-asparaginase activity in NSCs would result in a possible depletion of 
asparagine in the extracellular milieu, L-asparaginase activity in EVs has the 
additional benefit of releasing Asp, a metabolite whose role in supporting 
cells’ bioenergetics is increasingly recognised26,27. Hence, the biological 
consequences of Asn-depletion strategies using NSCs or EVs are likely to be 
very different. 
Besides Asn, the levels of several other metabolites with known biological 
functions were significantly altered by EVs. These include Asp, Glu, lactate, 
GABA and alanine. For instance, GABA and Glu are well-known 
neurotransmitters able to shape the activity of brain cells28, as well as the 
behaviour of other cell types29,30. Lactate is a potent signalling molecule able 
to affect the proliferation of cancer cells31, promote tumour angiogenesis32, 
and act as a pro-inflammatory signal to induce T cell migration33. Finally, 
uptake of Asp has been recently shown to be essential for cells with impaired 
mitochondrial function both in vitro and in vivo26,27. This evidence supports the 
hypothesis that, by altering the metabolic composition of the 
microenvironment, EVs might be able to profoundly shape the behaviour of 
surrounding cells, with potential important implications for biological functions 
of different cell types. 
Here we identified Asrgl1 as the key metabolic enzyme responsible of the 
EV-associated L-asparaginase activity. Asrgl1 was initially identified as novel 
L-asparaginase in the rat and human testis34, and lately found to exhibit 
specific activity for Asn17. We demonstrated that Asrgl1 is the only metabolic 
enzyme with known L-asparaginase activity expressed by mouse and human 
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NSCs, which both export towards EVs. Moreover, when equimolar amounts of 
labelled Asn and Gln are added to medium the relative L-asparaginase 
activity is higher compared to the Gls activity, further supporting that the L-
asparaginase activity is the predominant one in EVs. We also confirmed that 
Asrgl1 is the enzyme responsible for the Asn-specific L-asparaginase activity 
mediated by EVs, as indicated by our Asrgl1 Lof and GoF experiments. In 
fact, when the expression of Asrgl1 was reduced or enhanced we observed 
that, while Gln and Glu levels were unaltered, only Asn consumption and Asp 
production were affected.  
The finding that EVs-derived Asrgl1 is specific for Asn has important 
clinical implications. Various bacteria-derived L-asparaginases are currently 
used to treat acute lymphoblastic leukaemia and malignant lymphoma35. 
Furthermore, new reports demonstrated the L-asparaginase efficacy also 
toward glioblastoma cells in vitro36. The residual Gls activity of bacterial 
asparaginases is thought to be a major drawback of therapy since it leads to 
secondary immune depression and liver toxicity37. Therefore, the identification 
of Gls-free functional L-asparaginase into EVs might provide a valid 
alternative to recombinant L-asparaginases that would limit most of their side 
effects.  
Beyond the characterisation of EV-associated Asrgl1 activity, the 
mechanism of Asrgl1 action within the EVs compartment remains to be further 
elucidated. Considering its cytosolic localization, it is tempting to speculate 
that Asrgl1 may be contained in the lumen of EVs, where it remains 
functionally active as long as for at least 24 hours, a time frame that is 
compatible with the experiments here described. Indeed, Asrgl1 enzymatic 
activity is significantly enriched in EVs, as compared to EV-deprived NSC 
supernatants, which indicate that extracellular metabolic enzymes are not 
secreted as free proteins in the extracellular milieu. Furthermore, the 
observation that the intrinsic Asrgl1 activity is higher in EVs than in NSCs and 
in the recombinant protein, suggests that Asrgl1 in EVs might be exposed to 
an activating microenvironment, or subject to post-translational modifications 
that do not occur in vitro, making EVs ideal vessels to deliver this enzyme. 
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Applying heavy-light double stable isotope labelling of amino acids in cell 
culture (SILAC) comparing EVs and exosomes collected from NSCs, we have 
recently described that NSCs and NSC EVs express a few members of the 
solute carrier (SLC) family of membrane transporters, which include the high 
affinity Glu and Asp transporter (Slc1a3) and the two system A family 
members the Sodium-coupled neutral amino acid transporter 2 (Slc38a2), and 
the Sodium-coupled neutral amino acid transporter 3 (Slc38a3)6. It would be 
then plausible to hypothesize that metabolically active EVs uptake 
extracellular Asn via sodium–coupled neutral amino acid (system N/A) 
transporters (SNATs), hydrolyze Asn to Asp into Asrgl1-coargoed EVs and 
then export Asp via EV-associated Slc1a3 in the extracellular milieu. Further 
studies are necessary to validate this hypothesis, as well as to identify the 
possible mechanisms by which metabolic enzymes are loaded into (or 
sampled by) EVs. 
In conclusion, our work shows for the first time the intrinsic ability of NSCs 
to deliver functional L-asparaginase activity in the microenvironment via 
Asrgl1 in EVs. Our work further highlights a surprising novel role for stem cell-
derived EVs, with a potential role in the propagation of specific metabolic 
signals to the surrounding cells and to the microenvironment.  
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Figure Legends 
Figure 1. NSCs secrete EVs containing exosomes. (a, b) Particle-size 
distribution of EVs by NTA (a) and TRPS (b) technologies. The dimension 
data are expressed as mean values (nm) ± SEM from n= 3 independent 
experiments. (c) Western blot analysis of markers for exosomes and for 
different organelles (Golgi, endoplasmic reticulum and mitochondria) in mouse 
NSCs and EVs. This panel is representative of n= 3 independent protein 
preparations showing the same trends. Full gels are located in 
Supplementary Figure 7. 
 
Figure 2. NSC EVs are metabolically active in vitro. (a) Scatter plot of 
metabolomics experiment showing log2 fold changes of extracellular 
metabolites in medium + EVs vs. Vehicle as in a. Positive/negative values 
indicate production/consumption of metabolites, respectively. Data from two 
independent experiments are shown. (b) Barplot of the consumption of 15N2-
Asn and production of 15N-Asp mediated by EVs, conditioned medium (i.e. 
CM, medium with EVs) and supernatant (i.e. SN, medium deprived of EVs), 
with or without heat inactivation (100°C for 10’). Data are mean ± SEM and 
have been obtained from n= 2 independent experiments. Statistical analysis 
was performed using one-way ANOVA, followed by Bonferroni’s test 
correction. * p< 0.05; ** p < 0.01; *** p<0.001. (c) Consumption of Asn with 
different amounts of clinical-grade L-asparaginase produced by Erwinia 
chrysanthemi (Erwinase) was used to determine the L-asparaginase activity 
associated with EVs. One International Unit of L-asparaginase is defined as 
the amount of enzyme required to generate 1 mol of ammonia per minute 
at pH 7.3 and 37ºC. Solid line indicates Erwinase calibration curve, while 
square symbol and dashed line indicate interpolation of the calibration curve 
with Asn consumption values obtained with EVs.  
 
Figure 3. Mouse NSCs traffic Asrgl1 into EVs. (a) qPCR and (b) western 
blot analyses of Asrgl1 expression in mouse NSCs. qPCR data are 
represented as fold change ± SEM of the Aspg and Asrgl1 mRNA levels in 
NSCs, and analysed with the 2-ΔCt method over 18S ribosomal RNA, used as 
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housekeeping gene. Both qPCR and WB data have been obtained from n=3 
independent experiments. (c) Western blot of Asrgl1 and markers for 
exosomes and cellular organelles as in Figure 1, after sucrose gradient 
fractionation of total EVs. This panel is representative of n = 3 independent 
protein preparations showing the same trends. See also Supplementary 
Figure 3. Full gels are located in Supplementary Figure 8 and 9. 
 
Figure 4. Asrgl1 is responsible for the selective L-asparaginase activity 
associated with EVs. (a, b) Western blot analysis of shAsrgl1 (a) and Asrgl1 
GoF (b) NSCs and EVs. These panels are representative of n= 3 independent 
protein preparations showing the same trends. (c, d) Barplot of the 
consumption of 15N2-Asn and 
13C5-Gln followed by production of 
15N-Asp and 
13C5-Glu mediated by shAsrgl1 (c) and Asrgl1 GoF (d) EVs. Data are mean ± 
SEM and have been obtained from n 3 independent experiments. Statistical 
analysis was performed using t-test. * p< 0.05; ** p < 0.01. Full gels are 
located in Supplementary Figure 11 and 12. 
 
 
Online methods 
Cell culture preparations 
NSCs were prepared from the subventricular zone of 7- to 12-week-old SJL 
mice, as described1. Good Manufacturing Practice-grade, foetal human NSCs 
from natural in utero death (hNSCs) were prepared as described15. Both 
mouse and human NSCs were tested for Mycoplasma contamination, several 
times throughout the study, and always resulted Mycoplasma-free.  
 
Purification of EVs from media and sucrose gradient fractionation 
Mouse and human NSC EVs were collected and characterized as described5. 
 
Nanoparticle Tracking Analysis (NTA) 
Samples were diluted 1:1000 with PBS, vortexed and analysed by 
Nanoparticle Tracking Analysis (NTA) instrument (NS500, NanoSight ltd) 
fitted with an Electron Multiplication Charge-Couple Device camera and a 532 
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nm laser. The temperature was maintained within the range 20-25°C and 
resultant liquid viscosity calculated by the instrument. 3 repeated 
measurements of 60 seconds were recorded for each of the 3 independent 
samples (9 analysis in total). Fresh sample was loaded into the chamber prior 
to each video capture. Static mode (no flow) was used for analysis and 
detection threshold was adjusted to 5. Automatic settings were set for blur 
size, minimum track length and minimum particle size. The movement of each 
particle in the field of view was measured to generate the average 
displacement (in terms of x and y) of each particle per unit time. From this 
measurement, the particle diffusion coefficient was estimated and the 
hydrodynamic diameter calculated through application of the Stokes-Einstein 
equation. 
 
Tunable resistive pulse sensing (TRPS) 
The concentration and size distribution of EVs was analysed with TRPS 
(qNano, Izon Science Ltd) using a NP150 nanopore at 0.5 V with 47 mm 
stretch. The concentration of particles was standardized using 100 nm 
calibration beads (CPC 100) at a concentration of 1x1010 particles/mL. 
 
Protein purification and Western blot analysis 
Whole NSCs, EVs and sucrose gradient fraction extracts were processed as 
described5. Due to the limited amount of material obtained from sucrose 
gradient fractions, the correspondent WBs were performed using independent 
EV preparations starting from the same NSC batch. The following primary 
antibodies were used: mouse monoclonal anti-Pdcd6ip (BD transduction lab 
and Cell Signaling Technology); rat monoclonal and mouse monoclonal anti-
CD9 (BD transduction lab and Life Technologies, respectively); goat 
polyclonal anti-TSG101 (Santa Cruz); rat monoclonal and mouse monoclonal 
anti-CD63 (MBL and Life Technologies, respectively); rabbit polyclonal anti-
Asrgl1 (Proteintech); mouse monoclonal anti-GM-130 (BD transduction lab); 
rabbit polyclonal anti-calnexin (Abcam); rabbit polyclonal anti-Tom-20 (Santa 
Cruz); rabbit monoclonal anti-Gls (Abcam); mouse monoclonal anti-beta-Actin 
(Sigma). Molecular weight marker: SeeBlue Plus2 (Invitrogen). WB for mouse 
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and human Cd63 and Cd9 were run under non reducing conditions, i.e 
sample buffer used for electrophoresis was devoid of reducing agent.  
 
RNA extraction, RT and qPCR  
RNAs from mouse and human NSCs were obtained using the miRCURY™ 
RNA Isolation Kit - Cell & Plant (Exiqon). Total RNA quantity and purity were 
assessed with the NanoDrop 2000c instrument (Thermo Scientific). cDNA 
synthesis was performed using SuperScript™ III First-Strand Synthesis 
SuperMix for qRT-PCR (Invitrogen), with random hexamers as primers. 
qPCRwas performed with the TaqMan® Universal PCR Master Mix (Applied 
Biosystems) and TaqMan® Gene Expression Assays for FAM™ Aspg, Asrgl1, 
ASPG and ASRGL1 and VIC® euk 18S rRNA probes. Samples were tested in 
triplicate on a QuantStudio 7 Flex Real-Time PCR System (Applied 
Biosystems) and analysed with the 2-ΔCt method over 18S ribosomal RNA, 
used as housekeeping gene. 
 
Vector production, titration and NSC infection 
Lentiviral particles were obtained and used as described (Viral manipulation of 
neural stem/precursor cells, ISSN: 08932336, DOI: 10.1007/978-1-62703-
610-8_14). shAsrgl1 NSCs (Asrgl1 LoF) were obtained using the pLKO.1-puro 
third generation vector (Sigma) with the shRNA sequence TRCN32311 
(CCGGCCAGAGTTCAACGCAGGTTATCTCGAGATAACCTGCGTTGAACTC
TGGTTTTTG) targeting mouse Asrgl1. Asrgl1 GoF NSCs were obtained 
using the pCDH-EF1-MCS-T2A-GFP third generation vector (System 
Biosciences) with the coding sequence expressing the mouse Asrgl1. A 
Multiplicity of Infection (MOI) of 30 was used for both shAsrgl1 and Asrgl1 
GoF NSCs. 
 
LC-MS metabolomic analysis 
For the LC separation, column used was the Sequant ZIC-HILIC (150mm × 
4.6 mm, particle size 5 m) with a guard column (20 mm × 2.1 mm, 5 µm) 
from Merck Millipore (HiChrom, Reading, UK). Mobile phase A: 0.1% formic 
acid v/v in water. Mobile B: 0.1% formic acid v/v in acetonitrile. The flow rate 
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was kept at 300 L/min and gradient was as follows: 0 minutes 80% of B, 12 
minutes 50% of B, 26 minutes 50% of B, 28 minutes 20% of B, 36 minutes 
20% of B, 37-45 minutes 80% of B. The mass spectrometer (Thermo Q-
Exactive Orbitrap) was operated in a polarity-switching mode. Samples were 
randomised to avoid bias due to machine drift. Chromatographic peaks were 
integrated using XCalibur Quan software (Thermo).  
 
Untargeted metabolomics and metabolic tracing analyses 
DMEM high glucose (Life Technology) was incubated for 24 hours at 37ºC 
and 5% CO2 with or without isolated EVs, corresponding to 100 µg of protein 
extract. To compare metabolic activities of EVs, conditioned medium (CM) 
and supernatant (SN), medium was supplemented with 50 M 15N2-L-Asn and 
2.5mM 13C5-Gln and incubated for 24 hours at 37ºC and 5% CO2 with or 
without isolated EVs. For all other isotope tracing experiments medium was 
supplemented with equimolar concentrations of 15N2-L-Asn and
 13C5-Gln (50 
M). To assess NSC L-asparaginase activity 1.5*10e6 Ctrl or Asrgl1 GoF cells 
were seeded in 6-well plates and incubated at 37°C with medium containing 
50 M 15N2-L-Asn for 24 hours. At the end of incubation period cells or EVs 
were harvested and centrifuged for 5 minutes at 300g or 30 minutes at 
100000g, respectively. Supernatants were collected and NPC pellets were 
washed three times in PBS. Extracellular metabolites were extracted by 
diluting 50 L of supernatant in 750 L extraction buffer (EB, 
MeOH:ACCN:H2O, 50:30:20). NSC intracellular metabolites were extracted by 
re-suspending washed cellular pellets in EB (1mL/10e6 cells). Extracted 
samples were mixed at 4ºC for 15 minutes and proteins were precipitated by 
centrifugation at 16000g at 4ºC for 10 minutes. Supernatant was collected 
and submitted to LC-MS analysis. To investigate extracellular metabolic 
activity LC-MS peak areas of fresh medium compared to EVs spent medium 
were compared. Absolute quantification of metabolites was obtained by 
comparing external standard curves composed of at least 4 dilution points. 
Quantification of Asrgl1 activity in intact NSCs and EVs was performed by 
quantifying Asrgl1 protein abundance in the different fractions. Image J was 
used to quantify the signal of the active form (alpha-chain) of ASRGL1 and to 
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extrapolate the amount of Asrgl1 in NSCs and EVs. 15N-Asparagine 
consumption from NSCs, EVs, and recombinant protein was measured using 
LCMS and normalised to Asrgl1 content. 
 
Statistical analysis 
For untargeted metabolomics analysis statistical analysis was performed with 
the R package “muma” (https://cran.r-project.org/) by comparing levels of 
metabolites in fresh and EVs conditioned medium via student’s t test. 
Benjamini-Hochberg correction for multiple testing and FDR=0.05 were 
applied to determine statistical significance. For isotope tracing experiments 
statistical analysis was performed with Prism Graphpad and tests were 
applied as indicated in figure legends. 
 
Data Availability Statement 
Request for materials, associated protocols, and other supporting data should 
be sent to S. Pluchino (spp24@cam.ac.uk) or C. Frezza (cf366@MRC-
CU.cam.ac.uk). 
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